Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

• 1 October 2002
• journal article
• review article
• Published by Elsevier in Seminars in Oncology
• Vol. 29  (5 Suppl 14) , 55-60
• https://doi.org/10.1053/sonc.2002.35648

Abstract

Keywords

• SAFETY
• ANTIBODY
• PANCREATIC CANCER
• TREATMENT
• EPIDERMAL
• TOLERATED
• IMC C225